|
Fig. S9 Fgf, MAPK/Erk, and ROS signaling pathways do not regulate the activation of mTORC1 during fin regeneration. (A) Scheme of inhibitor treatments of SU5402 (a Fgf receptor1 inhibitor), U0126 (a MAPK/Erk inhibitor), and VAS2870 (an NADPH oxidase inhibitor: ROS signaling) during fin regeneration. (B-I) Longitudinal sections of DMSO or inhibitors treated wild-type fin regenerates that were immunohistochemically stained with an antibody against p-S6K (green) at 24 or 48 hpa. DAPI fluorescent signal (blue) indicates the presence of nuclei. The p-S6K signals in SU5402-, U0126-, and VAS2870-treated fins were approximately comparable to those in DMSO-treated fins at both 24 hpa (DMSO, n = 6; SU5402, n = 5; U0126, n = 3; VAS2870, n = 3) and 48 hpa (DMSO, n = 6; SU5402, n = 4; U0126, n = 3; VAS2870, n = 3), even though these inhibitors, at 48 hpa, prevented fin regeneration. Dashed white lines indicate the amputation planes. Scale bars: 100 µm.